|
|
 |
|
Viewing report
|
|
|
|
CNS Therapeutics - A World Market Review
Bizacumen Inc., Nov 2009, Pages: 305
While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression. Continuing switch over of patients from typical or traditional anti-psychotics to expensive and safer atypical anti-psychotics drugs, such as Zyprexa, Risperdal and Geodon is driving the market forward. Global market for anti-depressants, a dominant product category of CNS therapeutics is on a decline, succumbed by increasing generic competition, loss of patent protection of key drugs, and increased risk of suicidal tendencies among adolescents.
These and other market data and trends are presented in 'CNS Therapeutics: World Market Review' by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses
Customers who bought this item also bought
CNS Therapeutics - Global Strategic Business Report
Pain Management - Global Trends
Ophthalmic Pharmaceutical Drugs - A Global Market Perspective
The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Pharmaceuticals - Global Outlook
Pain Management - Global Strategic Business Report
ADHD Therapeutics - Global Strategic Business Report
Opthalmic Pharmaceutical Drugs - Global Strategic Business Report
Analgesics - A Worldwide Market Intelligence Report
Human Vaccines - Global Market Opportunities
|
|
|
|
